Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties
摘要:
Sulfonylamido(ureido) derivatives of histamine were synthesized by an original procedure in order to obtain tight-binding activators of the zinc enzyme carbonic anhydrase (CA), exploiting the binding energy of the alkyl/arylsulfonyl moieties with amino acid residues at the entrance of the active site. In contrast to the lead molecule, histamine, the new derivatives possessed higher affinity for three different CA isozymes, as evidenced by compairing the affinity constants of these compounds for isozyme CA II. (C) 1999 Elsevier Science Ltd. All rights reserved.
Ring Cleavage of<i>N</i>-Acyl- and<i>N</i>-(Arylsulfonyl)histamines with Di-<i>tert</i>-butyl Dicarbonate. A One-Pot Synthesis of 4-Acylamino- and 4-Arylsulfonylamino-1,2-diaminobutanes
作者:A. Warshawsky、J. Altman、N. Kahana、R. Arad-Yellin、A. Deshe、H. Hasson、N. Shoef、H. Gottlieb
DOI:10.1055/s-1989-27402
日期:——
The ring cleavage of N-aryl- and N-(arylsulfonyl)histamines with di-tert-butyl dicarbonate in aqueous acetonitrile containing KOAc provides a one-pot synthesis of 4-acylamino- or 4-arylsulfonylamino-1,2-bis(tert -butoxycarbonylamino)butanes. Removal of the Boc groups in these protected triamines with trifluoroacetic acid or dry HCl in MeOH, followed by alkylation with benzyl bromoacetate, and then hydrogenation leads to N 4-acyl-1,2,4-butanetriamine -N 1,N 1,N 2,N 2 -tetraacetic acids and the N 4-arylsulfonyl analogs, respectively.
<i>N</i><sup>α</sup>-arylsulfonyl histamines as selective β-glucosidase inhibitors
作者:M. O. Salazar、M. I. Osella、I. A. Ramallo、R. L. E. Furlan
DOI:10.1039/c8ra06625f
日期:——
A selective β-glucosidase inhibitor was discovered using the chemically engineered extracts approach.
使用化学工程提取方法发现了一种选择性β-葡萄糖苷酶抑制剂。
MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
申请人:Hadida-Ruah Sara
公开号:US20110172229A1
公开(公告)日:2011-07-14
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.